Medication & Safety
How Much Does Ozempic Cost? A Country-by-Country Guide
Ozempic costs $800–$1000 per month in the US without insurance. Costs vary widely globally. Here is the complete breakdo...
Ozempic (semaglutide) has a well-documented side effect profile from large clinical trials involving tens of thousands of patients. The majority of side effects are gastrointestinal, occur most during the first two to three months of treatment, and improve significantly as the body adapts.
Understanding what to expect — and when — makes side effects manageable rather than alarming. This guide covers what the evidence shows at each stage of treatment.
The Most Common Side Effects
In the STEP clinical trials, the following side effects occurred in more than 5% of participants taking semaglutide 2.4 mg:
- Nausea (44% of participants at some point during treatment)
- Diarrhoea (30%)
- Vomiting (24%)
- Constipation (24%)
- Abdominal pain (20%)
- Headache (14%)
- Fatigue (11%)
- Dyspepsia or indigestion (9%)
The percentages are cumulative over 68 weeks. At any given time, far fewer participants were experiencing side effects — by week 20, rates had dropped substantially compared to the first eight weeks.
Why These Side Effects Happen
GLP-1 receptors line the gastrointestinal tract. Semaglutide slows gastric emptying — the rate at which the stomach empties into the intestine. This causes nausea and fullness. When gastric motility is slowed, constipation often follows. When the body's other regulatory systems try to compensate, diarrhoea can occur during transitions.
These are predictable biological responses to GLP-1 receptor activation, not signs that the drug is causing damage.
The Timeline: When Side Effects Peak and Ease
Weeks 1–4 (0.25 mg starting dose): Side effects are typically mild to moderate. Nausea is most common. This period is designed to acclimatise your system.
Weeks 5–8 (dose escalation to 0.5 mg): The dose increase can trigger a temporary increase in symptoms. Nausea and reduced appetite are most pronounced during this window.
Weeks 9–16 (reaching 1 mg and beyond): Most patients find symptoms begin to ease. The stomach adapts to the slower gastric emptying. Nausea decreases substantially for the majority.
Beyond week 16: Side effects have largely resolved for most patients. The appetite suppression continues but nausea is typically minimal. Constipation may persist and benefits from dietary management.
How to Manage the Most Common Side Effects
Nausea: Eat small, bland meals. Avoid greasy, fried, or very sweet foods. Do not eat to the point of fullness — stop when 70% full. Eat slowly. Avoid lying down immediately after eating.
Constipation: Increase water intake significantly. Eat more vegetables and fibre. Walk daily. If constipation persists, your physician may recommend a stool softener.
Vomiting: If vomiting occurs more than once per day for multiple days, contact your physician. Persistent vomiting may require antiemetics or dose adjustment.
Fatigue: Ensure adequate protein intake (reduced appetite can lead to under-eating protein). Maintain consistent sleep. This typically improves as the body adapts.
Less Common but Serious Side Effects to Know About
Pancreatitis: Very rare. Symptoms are persistent severe abdominal pain radiating to the back. If this occurs, stop the medication and seek immediate medical attention.
Gallbladder disease: Rapid weight loss increases gallstone risk regardless of the medication used. Semaglutide is associated with a small increase in gallbladder events above what weight loss alone explains.
Thyroid: Semaglutide carries a theoretical risk based on animal studies for medullary thyroid carcinoma. It is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.
Hypoglycaemia: When semaglutide is combined with insulin or sulfonylureas (in diabetes management), hypoglycaemia risk increases. Alone, it does not cause significant hypoglycaemia.
GLP-1 Pathway Support and Side Effects
The side effect profile of GLP-1 pathway activation is consistent regardless of delivery method. METASLIM GLP-1 sublingual drops activate the same receptor pathway and may produce similar mild GI adaptation effects — particularly reduced appetite and some initial digestive adjustment — especially in the first weeks of the program. The physician guidance built into METASLIM's 8-week program helps patients navigate this adaptation period safely.